NasdaqGM:MNKD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	375	119	167	N/A	5
12/31/2025	319	70	126	N/A	6
12/31/2024	272	35	188	N/A	4
3/31/2024	225	8	3	40	N/A
12/31/2023	199	-12	-8	34	N/A
9/30/2023	177	-31	-32	10	N/A
6/30/2023	158	-47	-57	-27	N/A
3/31/2023	128	-71	-72	-61	N/A
12/31/2022	100	-87	-88	-81	N/A
9/30/2022	76	-98	-98	-91	N/A
6/30/2022	66	-88	-89	-78	N/A
3/31/2022	70	-94	-83	-67	N/A
12/31/2021	75	-81	-73	-62	N/A
9/30/2021	81	-79	-60	-49	N/A
6/30/2021	75	-86	-54	-47	N/A
3/31/2021	66	-61	-35	-30	N/A
12/31/2020	65	-57	-33	-28	N/A
9/30/2020	63	-45	-34	-33	N/A
6/30/2020	62	-44	-73	-72	N/A
3/31/2020	62	-46	-91	-88	N/A
12/31/2019	63	-52	-91	-88	N/A
9/30/2019	63	-47	-61	-58	N/A
6/30/2019	53	-61	-22	-20	N/A
3/31/2019	42	-71	-28	-28	N/A
12/31/2018	28	-87	-38	-38	N/A
9/30/2018	16	-110	-93	-93	N/A
6/30/2018	13	-119	-102	-102	N/A
3/31/2018	12	-131	-95	-95	N/A
12/31/2017	11	-117	N/A	-65	N/A
9/30/2017	20	-31	N/A	-48	N/A
6/30/2017	180	129	N/A	-47	N/A
3/31/2017	178	134	N/A	-39	N/A
12/31/2016	175	126	N/A	-78	N/A
9/30/2016	162	-205	N/A	-88	N/A
6/30/2016	N/A	-364	N/A	-85	N/A
3/31/2016	N/A	-363	N/A	-91	N/A
12/31/2015	N/A	-368	N/A	-57	N/A
9/30/2015	N/A	-128	N/A	-70	N/A
6/30/2015	N/A	-133	N/A	50	N/A
3/31/2015	N/A	-177	N/A	44	N/A
12/31/2014	N/A	-198	N/A	4	N/A
9/30/2014	N/A	-216	N/A	6	N/A
6/30/2014	N/A	-230	N/A	-127	N/A
3/31/2014	N/A	-203	N/A	-134	N/A
12/31/2013	N/A	-191	N/A	-129	N/A
9/30/2013	N/A	-190	N/A	-123	N/A
6/30/2013	0	-182	N/A	-124	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MNKDの予測収益成長率 (年間37.8% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: MNKDの収益 ( 37.8% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: MNKDの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: MNKDの収益 ( 14.5% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: MNKDの収益 ( 14.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MNKDの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

MannKind 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 9.8% to US$7.25

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Consensus forecasts updated

Price target decreased to US$5.50

Consensus estimates of losses per share improve by 15%

Recent updates

MannKind Outperforms As Tyvaso DPI Captures Market Share

New major risk - Financial position

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation to Report Q1, 2024 Results on May 08, 2024

MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024

MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

CEO & Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes

MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023

Price target increased by 9.8% to US$7.25

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023

Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)

CEO & Director notifies of intention to sell stock

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Full year 2022 earnings: EPS misses analyst expectations

MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022

MannKind Corporation Successfully Completes Phase 1 Study of Inhaled Clofazimine

Mannkind Corporation: Ready For Your Biotech Portfolio

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

MannKind Corporation to Report Q2, 2022 Results on Aug 09, 2022

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

Price target decreased to US$5.50

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Consensus estimates of losses per share improve by 15%

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

MannKind Corporation, Annual General Meeting, May 10, 2022

Consensus revenue estimates fall by 12%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MannKind Corporation Provides Update on Tyvaso DPI New Drug Application

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

MannKind Corporation to Report Q4, 2021 Results on Feb 24, 2022

MannKind: A Promising Player In The Inhalable Insulin Market

Forecast to breakeven in 2024

Price target increased to US$6.25

Third quarter 2021 earnings released: US$0.018 loss per share (vs US$0.049 loss in 3Q 2020)

Price target decreased to US$5.80

No longer forecast to breakeven

Consensus forecasts updated

High number of new and inexperienced directors

Consensus forecasts updated

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.048 loss in 2Q 2020)

Lytham Partners Summer 2021 Investor Conference